SynthesisAnnals of medicine2026
Baseline D-dimer as a predictor of immune checkpoint inhibitor efficacy in cancer.
Synthesis in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical features and prognostic factors for spinal metastasis from sarcomatoid carcinoma: identifying candidates suitable for surgical intervention.BMC musculoskeletal disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by enhancing antitumor immunity, yet durable responses are observed in only a fraction of patients. Identifying accessible and reliable biomarkers to predict therapeutic efficacy remains a critical unmet need. D-dimer, a fibrin degradation product reflecting systemic coagulation, has been associated with tumor progression and poor prognosis, but its predictive value in ICI-treated patients remains unclear.
methodsWe conducted a systematic review and meta-analysis of studies evaluating baseline D-dimer in cancer patients receiving ICIs. Eligible studies reported outcomes including overall survival (OS), progression-free survival (PFS), objective response rate (ORR), or disease control rate (DCR). Data extraction and quality assessment were performed independently, and pooled hazard and odds ratios were calculated. Sensitivity and subgroup analyses were conducted to evaluate the stability of findings and potential cutoff-dependent effects.
resultsTen retrospective studies including 1,217 patients were analyzed. Elevated baseline D-dimer was significantly associated with worse OS (HR = 1.95, 95% CI: 1.62-2.36,
conclusionsBaseline D-dimer is a readily measurable, cost-effective biomarker that predicts inferior outcomes in patients receiving ICIs. Its integration into clinical workflows may aid patient stratification and guide treatment decisions. Prospective multicenter studies are warranted to validate cutoff thresholds and further define its utility in optimizing immunotherapy efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.